From GlobeNewswire:

Vaxcyte, Inc., a clinical-stage vaccine company, closed a public offering of over 12.6 million shares of common stock at a price of $64.00 per share, bringing in approximately $862.5 million in gross proceeds. BofA Securities, Jefferies, and Leerink Partners LLC were among the book-running managers for the offering. Vaxcyte plans to use the funds for the development of a broad-spectrum conjugate vaccine, VAX-24, for the prevention of invasive pneumococcal disease. The company is also developing VAX-31, a 31-valent pneumococcal conjugate vaccine, along with other vaccine candidates to address bacterial infections. Full details about the offering can be found on the SEC’s website.



Read more: Vaxcyte Announces Closing of $862.5 Million Public Offering